The challenges of liver transplantation in children with primary sclerosing cholangitis

References

• Card TR, Solaymani-Dodaran M, West J. Incidence and mortality of primary sclerosing cholangitis in the UK: a population-based cohort study. J Hepatol 2008;48:939-44
   PubMed Web of Science ®Google Scholar
• Kaplan GG, Laupland KB, Butzner D, et al. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol 2007;102:1042-9
   PubMed Web of Science ®Google Scholar
• Deneau M, Jensen K, Holmen J, et al. Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in utah children: epidemiology and natural history. Hepatology 2013;58:1392-400
   PubMed Web of Science ®Google Scholar
• Talwalkar J, Lindor K. Natural history and prognostic models in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2001;15:563-75
   PubMed Web of Science ®Google Scholar
• Batres LA, Russo P, Mathews M, et al. Ruchelli E. primary sclerosing cholangitis in children: a histologic follow-up study. Pediatr Dev Pathol 2005;8:568-76
   PubMed Web of Science ®Google Scholar
• Feldstein AE, Perrault J, El-Youssif M, et al. Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology 2003;38:210-17
   PubMed Web of Science ®Google Scholar
• Miloh T, Arnon R, Shneider B, et al. A retrospective single-center review of primary sclerosing cholangitis in children. Clin Gastroenterol Hepatol 2009;7:239-45
   PubMed Web of Science ®Google Scholar
• Wilshanski M, Chait P, Wade JA, et al. Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis. Hepatology 1995;22:1415-22
   PubMed Web of Science ®Google Scholar
• Mieli-Vergani G, Vergani D. Paediatric autoimmune liver disease. Arch Dis Child 2013;98:1012-17
   PubMed Web of Science ®Google Scholar
• Gregoria GV, Portmann B, Karani J, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001;33:544-53
   PubMed Web of Science ®Google Scholar
• Bjornsson E, Angulo P. Cholangiocarcinoma in young individuals with and without primary sclerosing cholangitis. Am J Gastroenterol 2007;102:1677-82
   PubMed Web of Science ®Google Scholar
• Liu R, Cox K, Guthery SL, et al. Cholangiocarcinoma and high-grade dysplasia in young patients with primary sclerosing cholangitis. Dig Dis Sci 2014;59:2320-4
   PubMed Web of Science ®Google Scholar
• Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51:660-78
   PubMed Web of Science ®Google Scholar
• Faubion WA, Loftus EV, Sandborn WJ, et al. Pediatric “PSC-IBD”: a descriptive report of associated inflammatory bowel disease among pediatric patients with PSC. J Pediatr Gastroenterol Nutr 2001;33:296-300
   PubMed Web of Science ®Google Scholar
• Soetikno R, Lin O, Heidenreich P, et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gatrointest Endosc 2002;56:48-54
   PubMed Web of Science ®Google Scholar
• Singh S, Edakkanambeth J, Loftus EV, Talwalkar J. Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: a systematic review and meta-analysis. Liver Transpl 2013;19:1361-9
   PubMed Web of Science ®Google Scholar
• Rufo PA. Inflammatory bowel disease and neoplasia in children. Dig Dis 2014;32:455-62
   PubMed Web of Science ®Google Scholar
• Farraye F, Odze R, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010;138:738-45
   PubMed Web of Science ®Google Scholar
• Miloh T, Anand R, Yin W, et al. Pediatric liver transplantation for primary sclerosing cholangitis. Liver Transpl 2011;17:925-33
   PubMed Web of Science ®Google Scholar
• Venkat V, Ranganathan S, Mazariegos G, et al. Recurrence of primary sclerosing cholangitis in pediatric liver transplant recipients. Liver Transpl 2014;20:679-86
   PubMed Web of Science ®Google Scholar
• Graziadei I. Recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2002;8:575-81
   PubMed Web of Science ®Google Scholar
• Sheng R, Campbell WL, Zajko AB, Baron RL. Cholangiographic features of biliary strictures after liver transplantation for primary sclerosing cholangitis: evidence of recurrent disease. Am J Radiol 1996;166:1109-13
   Google Scholar
• Khettry U, Keaveny A, Goldar-Najafi A, et al. Liver transplantation for primary sclerosing cholangitis: a long-term clinicopathologic study. Hum Pathol 2003;34(11):1127-36
   PubMed Web of Science ®Google Scholar
• Demetris A. Distinguishing between recurrent primary sclerosing cholangitis and chronic rejection. Liver Transpl 2006;12:S68-72
   PubMed Web of Science ®Google Scholar
• Alabraba E, Nightingale P, Gunson B, et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl 2009;15:330-40
   PubMed Web of Science ®Google Scholar
• Alexander J, Lord JD, Yeh MM, et al. Risk factors for recurrence of primary scleosing cholangitis after liver transplantation. Liver Transpl 2008;14:245-51
   PubMed Web of Science ®Google Scholar
• Brandsaeter B, Schrumpf E, Bentdal O, et al. Recurrent primary sclerosing cholangitis after liver transplantation: a magnetic resonance cholangiography study with analyses of predictive factors. Liver Transpl 2005;11:1361-9
   PubMed Web of Science ®Google Scholar
• Cholongitas E, Shusang V, Papatheodoridis GV, et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2008;14:138-43
   PubMed Web of Science ®Google Scholar
• Kugelmas M, Spiegelman P, Osgood MJ, et al. Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2003;9:727-32
   PubMed Web of Science ®Google Scholar
• Egawa H, Uedab Y, Ichida T, et al. Risk factors for recurrence of primary sclerosing cholangitis after living donor liver transplantation in Japanese registry. Am J Transplant 2011;11:518-27
   PubMed Web of Science ®Google Scholar
• Campsen J, Zimmerman MA, Trotter JF, et al. Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl 2008;14:181-5
   PubMed Web of Science ®Google Scholar
• Jeyarajah D, Netto G, Lee S, et al. Recurrent primary sclerosing cholangitis after orthotopic liver transplantation: is chronic rejection part of the disease process? Transplantation 1998;27:1300-6
   Google Scholar
• Brandsaeter B, Friman S, Broome U, et al. Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries. Scand J Gastroenterol 2003;38:1176-83
   PubMed Web of Science ®Google Scholar
• Tabibian JH, O’Hara SP, Lindor KD. Primary sclerosing cholangitis and the microbiota: current knowledgeand perspectives on etiopathogenesis and emerging therapies. Scand J Gastroenterol 2014;49:901-8
   PubMed Web of Science ®Google Scholar
• Abarbanel DN, Seki SM, Davis Y, et al. Immunomodulatory effect of vancomycin on treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis. J Clin Immunol 2013;33:397-406
   PubMed Web of Science ®Google Scholar
• Martin CR, Blanco PG, Keach JC, et al. The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis – a pilot study. Aliment Pharmacol Ther 2012;35:255-65
   PubMed Web of Science ®Google Scholar
• Mizuno S, Hiano K, Tada M, et al. Bezafibrate for the treatment of primary sclerosing cholangitis. J Gastroenterol 2010;45:758-62
   PubMed Web of Science ®Google Scholar
• Davis YK, Cox KM, Abdullah BA, et al. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr 2008;47:61-7
   PubMed Web of Science ®Google Scholar
• Trauner M, Halilbasic E, Kazemi-Shirazi L, et al. Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies. Dig Dis 2014;2014:631-6
   Google Scholar
• Wunsch E, Trottier J, Milkiewicz M, et al. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Hepatology 2014;60:931-40
   PubMed Web of Science ®Google Scholar
• Spurkland A, Saarinen S, Boberg KM, et al. HLA class II haplotypes in primary sclerosiing cholangitis patients from five European populations. Tissue Antigens 1999;53:459-69
   PubMed Web of Science ®Google Scholar
• Boberg KM, Spurkland A, Rocca G, et al. The HLA-DR3,DQ2 heterozygous genotype is associated with an accelerated progression of primary sclerosing cholangitis. Scand J Gastroenterol 2001;36:886-90
   PubMed Web of Science ®Google Scholar
• Karlsen TH, Franke A, Melum E, et al. Genome wide association analysis in primary sclerosing cholangitis. Gastroenterology 2010;138:1102-11
   PubMed Web of Science ®Google Scholar
• Bowlus C, Li C, Karlsen TH, et al. Primary sclerosing cholangitis in genetically diverse populations listed for liver transplantation: unique clinical and human leukocyte antigen associations. Liver Transpl 2010;16:1324-30
   PubMed Web of Science ®Google Scholar
• Fosby B, Karlson TH, Melum E. Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol 2012;18:1-15
   PubMed Web of Science ®Google Scholar
• Miyagawa-Hayashino A, Egawa H, Yoshizawa A, et al. Frequent overlap of active hepatitis in recurrent primary sclerosing cholangitis after living-donor liver transplantation relates to its rapidly progressive course. Hum Pathol 2011;42:1329-36
   PubMed Web of Science ®Google Scholar